Actively Recruiting
Observational Study of Treatment Patterns and Biomarker Prevalence Across Bladder Cancer Stages in the Russian Federation
Led by AstraZeneca · Updated on 2026-09-14
600
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter observational study to examine treatment methods and the presence of HER2 positive status in various stages of bladder cancer, as well as PD-L1-positive status in metastatic bladder cancer among adult patients in the Russian Federation. The study includes patients with non-muscle-invasive bladder cancer NMIBC, muscle-invasive bladder cancer MIBC, or metastatic bladder cancer mBC to better understand how these biomarkers and treatments vary by disease stage. This study does not involve any new treatments or changes to routine care. Instead, it collects information from medical records and existing tumor tissue samples obtained during standard clinical procedures. The study will include about 600 adult patients from around 30 oncology centers, divided evenly into three groups based on their bladder cancer stage. Data collection happens during a single routine clinical visit without additional follow-up. Participants provide medical history, demographic details, and information on treatments they have received. Tumor tissue samples are sent to a central laboratory for testing. Researchers will analyze these data to measure treatment patterns and biomarker prevalence, including HER2 and PD-L1 status. The study aims to complete enrollment within 18 months or once 600 patients are included, with no ongoing patient visits beyond the initial data collection.
CONDITIONS
Brief Title
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here